Rôle du charbon actif administré par voie orale dans la réduction de l'urée, de la créatinine et du phosphore dans la maladie rénale chronique

Chronic Kidney Disease (CKD) is a growing health concern worldwide. This condition often leads to complications like heart diseases, malnutrition, and anemia. The build-up of toxins, such as indoxyl sulfate and p-cresyl sulfate, worsens the condition and increases the risk of heart diseases. Many patients refuse to start chronic hemodialysis, a common treatment for CKD. This study focuses on finding alternative treatments that can lower the levels of these toxins, potentially slowing down the progression of CKD. One such alternative is oral activated charcoal. The study also explores the use of dry seeds, like lentils, as a potential absorbent for these toxins. In this trial, participants with CKD will be given a daily dose of 30gm of oral activated charcoal. The study aims to measure the levels of blood urea, creatinine, and phosphorous in these patients before and after the treatment. This will help assess the effectiveness of oral activated charcoal in reducing these toxins. The study will also compare the effects of oral activated charcoal with dry seeds as an absorbent for uremic toxins. The potential benefits include a slower progression of CKD and improved overall health for patients.